AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: D. Kim who wrote (953)	11/19/1997 1:41:00 PM
From: D.Right	Read Replies (2) of 2173

Dear D.Kim: Of course Henry won't see anything new here, this is a positive article about the drug pramlintide from AMLN and Henry doesn't like pramlintide or anything AMLN may have for reasons he kept to himself. The only reason he posts here is to tell people AMLN is a really bad investment choice and they should all switch to LGND. I agree that most of the information in that article was available before if you have followed the company closely. But that is not the case for potential new investors who happened to read Barron that day. I am sure Henry would send out many many e-mails all over the places if it had been for LGND with or without new informations. What is new in the Barron's article, however, is that it was the first time we know how diabetic patients feel after they took pramlintide. It is true that you have to have the numbers for a FDA approval, I am sure AMLN is working for those number right now in the on-going trials, but it is what the drug can do for patients like the ones in Barron's article that will decide how successful a drug will be after the approval. And the article did tell us that. Good day D.Right

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next